Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.65 -2.6%	$2.21	$1.03 ▼ $2.99	$544.92M	1.44	2.10 million shs	2.72 million shs
KURA Kura Oncology	$6.13 -3.5%	$6.07	$5.41 ▼ $23.48	$549.75M	0.4	1.27 million shs	938,239 shs
LIMN Liminatus Pharma	$5.59 -11.7%	$0.00	$4.40 ▼ $33.66	$164.67M	N/A	330,121 shs	141,707 shs
TYRA Tyra Biosciences	$10.13 -7.1%	$9.83	$6.42 ▼ $29.60	$579.21M	1.07	291,119 shs	147,119 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	-2.57%	+0.76%	+25.59%	+86.62%	+64.60%
KURA Kura Oncology	-3.46%	+5.51%	-4.81%	+6.61%	-73.08%
LIMN Liminatus Pharma	-11.69%	-10.99%	+558,999,900.00%	+558,999,900.00%	+558,999,900.00%
TYRA Tyra Biosciences	-7.15%	+2.22%	-2.88%	+17.65%	-49.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.1775 of 5 stars	3.8	4.0	0.0	0.0	2.3	1.7	0.6
KURA Kura Oncology	4.5212 of 5 stars	4.4	2.0	0.0	4.7	2.9	0.8	0.6
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	3.132 of 5 stars	3.5	5.0	0.0	0.0	1.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.50	Strong Buy	$9.00	239.62% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	299.67% Upside
LIMN Liminatus Pharma	0.00	N/A	N/A	N/A
TYRA Tyra Biosciences	3.00	Buy	$30.83	204.38% Upside

Current Analyst Ratings Breakdown

Latest LIMN, TYRA, KURA, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,712.58	N/A	N/A	$0.69 per share	3.84
KURA Kura Oncology	$67.99M	7.81	N/A	N/A	$5.32 per share	1.15
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
LIMN Liminatus Pharma	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)

Latest LIMN, TYRA, KURA, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
KURA Kura Oncology	0.02	8.07	8.07
LIMN Liminatus Pharma	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	22.78	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
KURA Kura Oncology	N/A
LIMN Liminatus Pharma	N/A
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
KURA Kura Oncology	6.40%
LIMN Liminatus Pharma	N/A
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
KURA Kura Oncology	130	86.58 million	81.03 million	Optionable
LIMN Liminatus Pharma	N/A	26.01 million	N/A	N/A
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable

LIMN, TYRA, KURA, and ATAI Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?

July 15 at 2:10 PM | marketbeat.com

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Morningstar

July 9, 2025 | morningstar.comM

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

July 8, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?

July 3, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

July 2, 2025 | targetedonc.comT

Tyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancer

July 1, 2025 | pharmabiz.comP

Tyra Biosciences' (TYRA) "Buy" Rating Reiterated at HC Wainwright

July 1, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Rating of "Buy" by Brokerages

July 1, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

June 30, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Here's What Happened

June 23, 2025 | marketbeat.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of Stock

June 21, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in Stock

June 20, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

June 17, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 6,814 Shares

June 16, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $154,650.00 in Stock

June 16, 2025 | marketbeat.com

Gilla Kaplan Sells 30,000 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

June 16, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3% - What's Next?

June 16, 2025 | marketbeat.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, TYRA, KURA, and ATAI Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.65 -0.07 (-2.57%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.66 +0.01 (+0.38%)

As of 07/15/2025 08:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Kura Oncology NASDAQ:KURA

$6.13 -0.22 (-3.46%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$6.00 -0.13 (-2.10%)

As of 07/15/2025 07:03 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Liminatus Pharma NASDAQ:LIMN

$5.59 -0.74 (-11.69%)

As of 07/15/2025 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Tyra Biosciences NASDAQ:TYRA

$10.13 -0.78 (-7.15%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$10.12 -0.01 (-0.05%)

As of 07/15/2025 04:30 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time